Most Indians know about Hepatitis B — there is a vaccine for it, and it is part of the childhood immunisation schedule. But Hepatitis C is a different story. India has an estimated 5 to 6 million people living with chronic Hepatitis C infection, most of whom have no idea they are infected. Unlike Hepatitis B, there is no vaccine for Hepatitis C — but there is something arguably more remarkable: a cure. Modern oral medicines can clear Hepatitis C infection from the body in as little as 8–12 weeks, with a success rate exceeding 95%.
If you have ever had a blood transfusion before 2001, undergone medical procedures in settings with limited sterilisation, or if your doctor has mentioned "liver enzyme abnormality" in your reports, this guide is for you.
What Is Hepatitis C and How Is It Different From Hepatitis B?
Hepatitis C is caused by the Hepatitis C Virus (HCV), which primarily infects and damages liver cells. Like Hepatitis B, it is a bloodborne virus — it spreads through contact with infected blood. But there are critical differences:
| Feature | Hepatitis B | Hepatitis C |
|---|---|---|
| Vaccine available | Yes (3-dose schedule) | No vaccine |
| Transmission | Blood, sexual contact, mother-to-child | Primarily blood |
| Chronicity | 5–10% of adults become chronic | ~75–85% of adults become chronic |
| Cure available | No (managed, not cured) | Yes — >95% cure with DAAs |
| Silent infection | Common | Very common |
The most important fact about Hepatitis C is that it is curable. The Direct-Acting Antivirals (DAAs) — a new generation of oral medications introduced after 2015 — have transformed HCV from a chronic, managed condition into a disease that can be eliminated from the body in a matter of weeks.
How Hepatitis C Spreads in India
Hepatitis C is a bloodborne infection. It does not spread through coughing, sneezing, sharing food, hugging, or casual contact. The main routes of HCV transmission in India are:
- Unsafe blood transfusions: India's blood supply was not systematically screened for HCV until after 2001. Anyone who received a blood transfusion before 2001 should consider getting tested
- Reuse of syringes and needles: This remains a concern in some healthcare settings and among people who inject drugs (PWID). India has a significant injection drug use population in states like Punjab, Manipur, and Nagaland
- Unsafe medical and dental procedures: Shared equipment, poorly sterilised instruments, and certain traditional practices
- Tattooing and body piercing with non-sterile equipment
- Mother-to-child transmission: About 5–6% risk, lower than Hepatitis B
- Sexual transmission: Possible but less efficient than Hepatitis B; risk is higher with multiple partners or concurrent STIs
Who is at highest risk in India?
- People who received blood transfusions before 2001
- People who inject drugs (intravenous or intranasal)
- People with a history of dialysis
- Healthcare workers with needlestick exposure
- People who have had invasive dental or surgical procedures in informal settings
- People in Punjab and other states with known high HCV prevalence (estimated 3–4% in Punjab vs ~0.5% national average)
Hepatitis C Symptoms: The Silent Infection
Here is why Hepatitis C is so dangerous: most people have no symptoms for decades. Unlike the acute illness that sometimes accompanies Hepatitis A or acute Hepatitis B, acute HCV infection is typically silent. Most people who develop chronic HCV infection do not experience significant symptoms until the liver is already severely damaged.
When symptoms do appear, they may include:
- Persistent fatigue and weakness
- Mild upper-right abdominal discomfort
- Jaundice (yellowing of skin or eyes) — usually only in advanced disease
- Dark-coloured urine
- Nausea and loss of appetite
The real danger is the long-term progression:
| Stage | Timeframe | What Happens |
|---|---|---|
| Acute infection | 0–6 months | Usually symptom-free; ~15–25% clear spontaneously |
| Chronic infection | 6 months onwards | Slow, silent liver inflammation |
| Cirrhosis | 20–30 years | Permanent scarring; liver function impaired |
| Liver failure | Late stage | Ascites, bleeding, hepatic encephalopathy |
| Liver cancer (HCC) | Advanced cirrhosis | Significantly increased risk |
Approximately 15–20% of people with chronic Hepatitis C will develop cirrhosis within 20 years. Of those with cirrhosis, about 1–3% per year develop liver cancer (hepatocellular carcinoma or HCC). Early detection and cure with DAAs dramatically reduces this risk.
Hepatitis C Tests in India: Understanding Your Report
Testing for Hepatitis C involves two main types of tests:
1. Anti-HCV Test (Hepatitis C Antibody Test)
This is the first-line screening test for Hepatitis C.
| Parameter | Details |
|---|---|
| What it detects | Antibodies your immune system makes against HCV |
| What a positive means | You have been exposed to HCV at some point |
| What a negative means | Very likely HCV-free (unless very recent exposure) |
| Cost in India | ₹200–₹1,000 (SRL, Thyrocare, Dr. Lal PathLabs, Metropolis) |
| Availability | Widely available at all major pathology labs |
Important: A positive anti-HCV test does not confirm active infection. About 15–25% of people who get HCV clear it spontaneously. To confirm whether you have a current active infection, you need the next test.
2. HCV RNA Test (PCR Test)
The HCV RNA test is the confirmatory test that detects the actual virus in your blood.
| Parameter | Details |
|---|---|
| What it detects | Hepatitis C virus RNA (genetic material) |
| What a positive means | Active, ongoing HCV infection — you need treatment |
| What a negative means | Either cleared or never infected (if anti-HCV was a false positive) |
| Cost in India | ₹2,000–₹5,000 (higher than anti-HCV) |
| Reporting | Results typically as "detected/not detected" plus viral load (IU/mL) |
If both anti-HCV and HCV RNA are positive, you have active Hepatitis C and should begin treatment.
3. HCV Genotype Test
HCV has 6 major genotypes (numbered 1–6), and they differ in which drugs work best and for how long. India predominantly has Genotype 1 and Genotype 3.
| Parameter | Details |
|---|---|
| What it detects | Which HCV genotype you have |
| Why it matters | Determines optimal treatment regimen and duration |
| Cost in India | ₹3,000–₹8,000 |
| When it is ordered | After HCV RNA is confirmed positive, before starting treatment |
Note: With modern pan-genotypic DAA regimens (like sofosbuvir + velpatasvir), treatment works against all genotypes. Your doctor may opt for a pan-genotypic regimen without genotyping — especially under the free government programme.
4. Liver Function Tests (LFTs) and Liver Fibrosis Assessment
Once HCV is confirmed, your doctor will assess how much liver damage has occurred:
- LFT (SGPT/ALT, SGOT/AST, bilirubin) — measures liver inflammation. See our liver function test guide for interpreting these values
- FIB-4 score — calculated from age, AST, ALT, and platelet count; estimates degree of liver fibrosis without a biopsy
- FibroScan (liver elastography) — ultrasound-based test measuring liver stiffness; cost ₹2,000–₹5,000 in India
- Liver biopsy — rarely needed now with FibroScan available
Treatment: The Hepatitis C Cure
This is the most important section of this guide. Hepatitis C is now curable in over 95% of patients, regardless of genotype, with a short course of oral tablets.
Direct-Acting Antivirals (DAAs): How They Work
DAAs are oral antiviral medications that block specific proteins the Hepatitis C virus needs to replicate. Unlike older treatments (interferon injections, which caused severe side effects), DAAs are:
- Taken as once-daily oral tablets (no injections in most regimens)
- Short course: 8–12 weeks duration
- Highly effective: 95–99% cure rates in clinical trials, 90%+ in real-world Indian programmes
- Well-tolerated: Minimal side effects compared to old interferon-based therapy
- Safe for most patients, including those with cirrhosis (with appropriate monitoring)
DAA Regimens Available in India
| Regimen | Trade Names in India | Genotype Coverage | Duration |
|---|---|---|---|
| Sofosbuvir + Velpatasvir | Velasof, Sofosvel | Pan-genotypic (1–6) | 12 weeks |
| Sofosbuvir + Daclatasvir | Hepcinat-DP, Daclavir | Genotype 1, 3, 4 | 12 weeks |
| Sofosbuvir + Ledipasvir | Ledihep, Hepcinat-LP | Genotype 1, 3, 4, 5, 6 | 8–12 weeks |
| Glecaprevir + Pibrentasvir | Maviret (imported) | Pan-genotypic | 8 weeks |
Generic versions of these medicines have made treatment dramatically affordable in India:
- Brand-name DAAs in Western countries can cost ₹50–₹80 lakh for a course
- Generic DAAs in India cost ₹7,000–₹30,000 for a full course through private pharmacies
- Government programme (NVHCP): Free for eligible patients (see below)
What "Cure" Means: SVR12
Cure in Hepatitis C is defined as "Sustained Virological Response at 12 weeks" (SVR12) — meaning HCV RNA remains undetectable 12 weeks after completing treatment. Patients who achieve SVR12 are considered cured, as relapse is extremely rare (less than 1–2%).
After a cure:
- Liver inflammation halts and often partially reverses
- Risk of developing cirrhosis drops significantly
- If you already have cirrhosis, your risk of liver failure and liver cancer (HCC) decreases, though it does not return to baseline — you still need 6-monthly liver ultrasound and AFP monitoring
Free Treatment Through NVHCP
You do not have to pay for Hepatitis C treatment if you are eligible. The Government of India's National Viral Hepatitis Control Programme (NVHCP), launched in 2018, offers:
- Free HCV testing (anti-HCV and HCV RNA) at participating government hospitals
- Free DAA treatment for all viremic HCV-positive patients meeting eligibility criteria
- Free monitoring tests during treatment
- Available at District Hospitals, Medical Colleges, and NVHCP-designated centres across all states
To access free treatment:
- Visit your nearest government hospital or District Hospital
- Ask for referral to the NVHCP programme
- Get tested — anti-HCV screening is free at NVHCP centres
- If HCV RNA positive, treatment is initiated free of charge
States with high burden — Punjab, Haryana, Uttar Pradesh, Delhi — have particularly strong NVHCP infrastructure with dedicated hepatitis clinics.
Hepatitis C and Liver Health: Monitoring After Cure
After successfully completing DAA treatment and achieving SVR12, ongoing monitoring is important:
- Repeat LFT at 6 months post-treatment to confirm liver enzyme normalisation
- If you had cirrhosis before treatment: 6-monthly liver ultrasound + serum AFP (alpha-fetoprotein) for HCC surveillance — this is lifelong, even after cure
- Avoid alcohol entirely — liver cells are more vulnerable even after HCV cure
- Re-infection is possible if risk behaviours continue (sharing needles, etc.) — HCV cure does not give immunity to re-infection
Track your LFT trends, viral load tests, and post-treatment liver scans by uploading your reports to MedicalVault. The trend analysis feature helps you and your hepatologist monitor SGPT and SGOT levels over months — making it easy to confirm your liver is recovering after treatment. Use MedicalVault's family sharing feature to keep your hepatologist and family members informed with a shared view of your test history.
Should You Get Tested?
Yes, if any of the following apply to you:
- You received a blood transfusion before 2001 in India
- You have ever shared needles or syringes
- You have had haemodialysis
- You are a healthcare worker with history of needlestick injuries
- You have unexplained elevated liver enzymes (SGPT/ALT) in your blood reports
- You have a family history of liver disease or cirrhosis
- You live in Punjab or other high-prevalence states and have not been tested
- You have had unexplained fatigue for months with no clear cause
A simple anti-HCV test costing as little as ₹200–₹500 at most pathology labs — or free at government hospitals — can tell you your status. If positive, the HCV RNA test confirms whether you need treatment. And with a cure rate above 95% and free treatment available through NVHCP, a Hepatitis C diagnosis is very far from a death sentence.
Consult a hepatologist or gastroenterologist for evaluation, treatment planning, and follow-up monitoring. If you are outside a major city, government district hospitals with NVHCP centres are your best starting point.
Key Takeaways
- Hepatitis C is a curable disease — modern DAA medications eliminate HCV from the body in 8–12 weeks with a success rate exceeding 95%; no injections, no severe side effects
- India has 5–6 million HCV-infected people, most of them undiagnosed — if you have had a blood transfusion before 2001, dialysis, or shared needles, get tested
- Two-step testing: Start with an anti-HCV antibody test (₹200–₹1,000), confirm with HCV RNA PCR (₹2,000–₹5,000) if positive
- NVHCP offers free testing and treatment at government hospitals nationwide — you do not need to pay for treatment if eligible
- Generic DAAs in India cost just ₹7,000–₹30,000 for a full cure, versus lakhs abroad — making treatment within reach for most patients
- After cure (SVR12), liver damage halts — but patients with cirrhosis still need lifelong liver cancer surveillance (6-monthly ultrasound + AFP)
- Re-infection is possible — a cure does not protect against future exposure; risk reduction remains important
- Track your LFT trends, viral load, and post-treatment liver reports with MedicalVault to monitor your recovery and share results with your hepatologist